| Jun 24 |
eFFECTOR Therapeutics to wind down operations, expects to be delisted from Nasdaq
|
| Jun 24 |
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
|
| May 20 |
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
|
| May 10 |
eFFECTOR Therapeutics GAAP EPS of -$2.16 beats by $0.01
|
| May 9 |
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
